Analyst Price Targets — CGEN
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| January 7, 2026 11:08 am | — | H.C. Wainwright | $4.00 | $1.55 | TheFly | Compugen initiated with a Buy at H.C. Wainwright |
| May 21, 2024 7:48 am | Asthika Goonewardene | Truist Financial | $4.00 | $1.74 | TheFly | Compugen price target lowered to $4 from $5 at Truist |
| May 20, 2024 3:43 pm | Stephen Willey | Stifel Nicolaus | $4.00 | $1.74 | StreetInsider | Stifel Reiterates Buy Rating on Compugen (CGEN) |
| May 20, 2024 1:21 pm | Asthika Goonewardene | Truist Financial | $5.00 | $1.74 | StreetInsider | Compugen (CGEN) PT Raised to $5 at Truist Securities |
Latest News for CGEN
Compugen (NASDAQ: CGEN) executives used the company's fourth-quarter and full-year 2025 earnings call to highlight a strengthened balance sheet following a non-dilutive transaction with AstraZeneca, clinical progress across its wholly owned and partnered oncology programs, and strategic priorities that center on advancing its COM-701 ovarian cancer study and supporting Gilead-partnered GS-0321 development.…
Compugen remains a 'Buy,' supported by pipeline progress, major pharma partnerships, and a cash runway extended into 2029. Key catalysts include the phase 3 MAIA-Ovarian cancer trial (COM701), with interim analysis expected in Q1 2027, and the anti-IL18BP antibody GS-0321 in phase 1. CGEN's non-dilutive deal with AstraZeneca monetizes rilvegostomig royalties, enhancing financial stability and preserving future…
Compugen Ltd. (CGEN) Q4 2025 Earnings Call Transcript
Compugen (CGEN) came out with quarterly earnings of $0.6 per share, beating the Zacks Consensus Estimate of $0.05 per share. This compares to a loss of $0.07 per share a year ago.
Strengthened financial position through a non-dilutive transaction with AstraZeneca, monetizing a small portion of rilvegostomig royalties and extending expected cash runway into 2029 Enhanced leadership team with Dr. Eran Ophir appointed President and CEO and Dr. Anat Cohen-Dayag transitioned to Executive Chair Advanced clinical execution, including initiation of trials for wholly owned COM701 (MAIA-ovarian) and…
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for CGEN.
Senate Trading
No Senate trades found for CGEN.
U.S. House Trading
No House trades found for CGEN.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.